Objective
"Cancers of the Head and Neck Region (HNC) are the 6th more deadly cancers worldwide: in Europe ~150.000 new cases are detected and ~70.000 patients die every year. The main reasons for high mortality are the fact that the majority of cases are diagnosed in advanced Stage and the intrinsic heterogeneity of such tumors. At present the only adopted treatment decision method is based on TNM (Tumor-lymph-Nodes-Metastasis) prognostic system, that considers only a few risk factors such as smoking, alcohol abuse and more recently HPV. The TNM system is therefore inadequate to capture the patient-specific biomolecular characteristics of the tumor. HNC treatments can have hard impact on patient’s aesthetics and functionalities and, due to their toxicity, can cause severe morbidity and greatly deteriorate patient’s quality of life. A more precise prognostic prediction than the current TNM system is needed that allows implementing the first-line treatment that maximizes the therapeutic result and minimizes the impacts of therapy.
BD2Decide DSS provides clinicians with the ""means"" and all the necessary information to tailor treatment and care delivery pathway to each and any HNC patient during their usual practice, in contrast to current “one-size-fits-all approach”. BD2Decide realizes and validates an Integrated Decision Support System that links population-specific epidemiology and behavioral data, patient-specific genomic, pathology, clinical and imaging data with big data techniques, multiscale prognostic models. Advanced graphical visualization tools are developed for prognostic data disclosure and patient co-participation to the selected treatment. BD2Decide will improve the clinical decision process, uncover new patient-specific patterns that can improve care, and create a virtuous circle of learning. A multicentric clinical study with more than 1.000 patients will be used to validate the system.
"
Fields of science
- medical and health scienceshealth sciencespublic healthepidemiology
- natural sciencescomputer and information sciencesdata sciencebig data
- medical and health sciencesbasic medicinepathology
- medical and health sciencesclinical medicineoncologyhead and neck cancer
- medical and health scienceshealth sciencesinfectious diseasesDNA viruses
Programme(s)
Topic(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
43100 Parma
Italy
See on map
Participants (12)
Participation ended
1081 HV Amsterdam
40225 Dusseldorf
See on map
20133 Milan
See on map
28040 Madrid
See on map
80686 Munchen
See on map
15233 Athina
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
46733 Hertzelia
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
6229 ET Maastricht
See on map
20133 Milano
See on map
43121 Parma
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
43100 Parma
See on map
1081 HV Amsterdam
See on map